AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 81 min read$BWXT

BWX Technologies (NYSE: BWXT) director adds dividend-linked stock rights

BWX Technologies (BWXT) director Gerhard F. Burbach received 23.19 Dividend Equivalent Rights (DERs) on September 4, 2026, tied to restricted stock units. He now holds 801.11 DERs, each representing a contingent right to one share of BWXT common stock. The DERs will be delivered proportionately with the related RSUs.

Original reporting
stocktitan.net
Published Sep 8, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BWXT
Neutral
high confidence
Mentioned
$BWXT
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$BWXTNeutralLow
01

Why it matters

The award is a routine compensation event with negligible market impact, serving primarily as a disclosure requirement.

02

Market read

Limited relevance; primarily of interest to shareholders monitoring insider compensation.

03

What to watch

Potential future dilution when the DERs convert to shares, though the amount is minimal relative to total float.

Relevance 4/10Novelty 4/10Timing: September 4, 2026 (grant date)

Background

BWX Technologies disclosed a Form 4 filing showing a director's award of dividend equivalent rights tied to deferred RSUs.

Company-level read

Ticker impact

$BWXTNeutralHigh confidence
Context

Director Gerhard F. Burbach received a grant of 23.19 dividend equivalent rights on Sep 4, 2026, increasing his holdings to 801.11 DERs.

Expected impact

Minimal effect on BWXT share price; likely no noticeable movement.

Evidence & confidence

Form 4 award of a few dozen DERs is routine insider compensation with no cash transaction and no immediate share issuance.

Market effects

Sector

None; the grant is company‑specific and does not affect the broader nuclear/defense sector.

Regional

None; limited to BWXT shareholders.

Global

None; isolated insider compensation event.

Counterpoint

What could challenge this read

Even small insider grants can signal confidence in future performance, but the size here is too trivial to infer any material outlook.

Key entities

  • Director
    Gerhard F. Burbach

    Recipient of the dividend equivalent rights award.

  • Company
    BWX Technologies, Inc.

    Issuer of the DERs and subject of the Form 4 filing.

Read at source← All news

Related articles

SEP 15
$BWXTMed

Jim Cramer Favors BWX Technologies (BWXT) Over Cameco (CCJ)

Jim Cramer prefers BWX Technologies (BWXT) over Cameco (CCJ) for nuclear power investment, citing BWXT's stronger recent performance and Cameco's longer-term potential. BWXT reported Q2 revenue of $901.6M, up 18% YoY, and raised 2026 guidance. Cameco's Q2 uranium segment revenue fell to C$252M from C$352M YoY, but maintained production outlook. Both companies saw increased hedge fund interest.

insidermonkey.com2 min
SEP 15
$BWXTHigh

BWXT Looks 4.3% Undervalued on GF Value™

Guggenheim initiated coverage on BWX Technologies (BWXT) with a Buy rating and $192 price target, citing its strategic nuclear sector position. GF Value™ indicates BWXT is 4.3% undervalued at $148.53 vs. $155.28 intrinsic value. The company has a GF Score™ of 93/100, strong growth, and profitability but faces insider selling and premium valuation concerns.

gurufocus.com2 min
SEP 14
$BWXTMed

Bwxt stock hits 52-week low at 146.1 USD

BWX Technologies Inc. (BWXT) stock hit a 52-week low of $145.91, down 40% from its high. Q2 2026 earnings beat estimates at $1.07 EPS, but revenue missed at $901.6M. Sales rose 18% YoY, and the company raised full-year free cash flow guidance to $345M-$360M. BWXT's backlog grew to $8.4B, up 40% YoY. Jefferies initiated coverage with a Buy rating, and Wells Fargo upgraded to Equal Weight.

uk.investing.com2 min
SEP 10
$BWXTMed

Can BWXT's Canadian Lab Role Strengthen Nuclear Services Growth?

BWX Technologies (BWXT) is expanding its nuclear services through a new Canadian lab management role via a joint venture. The contract began in December 2025, complementing BWXT's broader strategy. The Kinectrics acquisition, completed in May 2025, is key to this expansion. BWXT's commercial revenues grew 62.8% YoY to $853.1M in 2025, with Kinectrics contributing $231M. Analysts expect EPS growth of 18.45% and 10.73% for 2026 and 2027, respectively.

finance.yahoo.com2 min
SEP 7
$CCJMed

Jefferies Sees Cameco (CCJ) and BWXT as Winners in the Nuclear Boom

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.

finance.yahoo.com3 min
SEP 6
$BWXTHighAI 8/10

BWX Technologies Already Builds Reactors for the Navy. Why Is It Still the Cheapest Nuclear Stock?

BWX Technologies (NYSE: BWXT) is the lowest-valued nuclear stock despite its monopoly in supplying nuclear reactors and fuel to the U.S. Navy. Its Q2 revenue rose 18% YoY to $901.6M, with EPS up 5% to $1.07. The company has an $8.6B backlog and raised its yearly revenue guidance to $3.8B. BWX also expanded into commercial markets, with Q2 commercial revenue up 72% YoY to $303M.

currently.att.yahoo.com2 min